ASH - Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

Kura Oncology, Inc. (NASDAQ:KURA) is up ~16% in pre-market trading after announcing encouraging preliminary clinical data for KO-539 in a Phase 1/2A clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).The data presented during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition were the first-in-human data generated by KO-539, a novel, once-daily, oral menin inhibitor for the treatment of genetically defined AML patients with a high unmet need.The enrollment is ongoing in the dose escalation of Phase 1/2A clinical trial to determine the safety, tolerability and recommended Phase 2 dose of KO-539, and an expansion phase in specific genetic subgroups is expected in the first quarter of 2021. On the safety front, there have been no drug discontinuations due to treatment-related adverse events, and the continuous daily dosing of KO-539 has been well tolerated with a manageable safety profile to date.“The preliminary clinical

For further details see:

Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate